Navigation Links
Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
Date:12/16/2010

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that enrollment and treatment of patients in a Phase 1b clinical trial has been initiated to evaluate JX-594 in patients with advanced metastatic, refractory colorectal cancer (CRC).  The study will be performed in Korea, where Green Cross Corporation holds market rights for JX-594.

"The initiation of this study marks an important step forward in the development of JX-594 for a second major oncology indication. With a significant and growing population of colorectal cancer patients who have failed existing therapies or for whom existing therapies are not appropriate, we believe JX-594, with its unique mechanisms of action and demonstrated tumor response in preclinical models of CRC, may provide an important new therapeutic modality for patients around the world suffering from this devastating cancer," said David H. Kirn, M.D., president and chief executive officer of Jennerex.

"The study design for this trial builds on our joint experience and positive clinical results using JX-594 to treat liver cancer and represents an important milestone which is our ability to administer multiple doses intravenously," added Philippe Archinard, chairman and chief executive officer of Transgene.

The intravenous, open-label, multi-dose-escalation study is being conducted at Samsung Cancer Center in Seoul, South Korea. The study will enroll up to 15 patients with metastatic colorectal cancer that have failed both oxaliplatin-based and irinotecan-based chemotherapy regimens, and whose tumors harbor ras mutations and/ or are refractory to Erbitux therapy. Patients en
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
2. Jennerex Appoints Lara Longpre to Chief Operating Officer
3. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
4. Jennerex Announces Presentations at Upcoming Conferences
5. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
8. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
11. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... New York, New York (PRWEB) July 13, 2014 ... much to bring attention to the cancer risks associated ... a chance to tell their story to federal regulators, ... of a U.S. Food & Drug Administration (FDA) ... Liebhard LLP reports. According to the Rochester Democrat ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... TX (PRWEB) July 13, 2014 The Pearland, ... children ranging in age from four months to 12 years ... and karate classes to birthday parties and Summer Camps, is ... Little Gym of Pearland after spending over six ... of roles, including Gym Director. , Berry has over ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... WEST CONSHOHOCKEN, Pa., May 1 Cadient Group, ... announced today it has appointed Barbara Dowling as ... in the healthcare,vertical on both the client and ... the digital channel to address business critical,issues. In ...
... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced the dates and ... and Annual Meeting of Shareholders., First Quarter Results ... a.m. (ET) Labopharm will host a conference,call to discuss ... first quarter 2008 financial results via news release at,approximately ...
... (Nasdaq: GTIV ), the nation,s leading provider of,comprehensive home ... quarter ended March 30, 2008:, (Logo: ... to $323.7 million versus the first quarter ... 13% to $7.7 million, or $0.27 per diluted share, ...
... intensive care will experience delusions or hallucinations, which put ... to a new study of childrens experiences in a ... which appears in the first issue for May of ... published by the American Thoracic Society, is believed to ...
... may also mask its severity in standard tests, according to ... women with a range of body mass indexes (BMIs). , ... comparative difference in how the airways and lungs respond to ... , The research is reported in the first issue for ...
... Christopher,s Hospital for Children and Independence Blue,Cross (IBC) ... principle,on terms of new contracts. They have extended ... multi-year contracts. Hahnemann and St.,Christopher,s are both part ... network of hospitals. The parties will continue to ...
Cached Medicine News:Health News:Cadient Group Appoints Barbara Dowling to Senior Vice President Customer Engagements 2Health News:Labopharm announces details for first quarter results conference call and annual meeting 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 2Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 3Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 4Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 5Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 6Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 7Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 8Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 9Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 10Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 11Health News:Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook 12Health News:Haunted by hallucinations: Children in the PICU traumatized by delusions 2Health News:Obesity worsens impact of asthma 2Health News:Hahnemann University Hospital and St. Christopher's Hospital for Children Extend Current Agreement With Independence Blue Cross 2Health News:Hahnemann University Hospital and St. Christopher's Hospital for Children Extend Current Agreement With Independence Blue Cross 3
... represents an rhBMP-2 (recombinant human bone morphogenetic ... absorbable collagen sponge (ACS) carrier. The Infuse ... indicated for spinal fusion procedures in skeletally ... at one level from L4-S1, who may ...
... Graftech cervical dowels are ... to graft expulsion and improve ... allows immediate red blood cell ... Grafton DBM gel into the ...
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... Cranial Fixation Systems incorporate a great ... by surgeons and surgical staff. Additionally, ... be either shaped on the spot ... pre-measured, cut, bent and shaped implant ...
Medicine Products: